Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 65

1.

Synthesis and apoptosis inducing ability of new anilino substituted pyrimidine sulfonamides as potential anticancer agents.

Kamal A, Dastagiri D, Ramaiah MJ, Reddy JS, Bharathi EV, Reddy MK, Sagar MV, Reddy TL, Pushpavalli SN, Pal-Bhadra M.

Eur J Med Chem. 2011 Dec;46(12):5817-24. doi: 10.1016/j.ejmech.2011.09.039. Epub 2011 Sep 29.

PMID:
22000207
3.

Synthesis of imidazothiazole-chalcone derivatives as anticancer and apoptosis inducing agents.

Kamal A, Dastagiri D, Ramaiah MJ, Reddy JS, Bharathi EV, Srinivas C, Pushpavalli SN, Pal D, Pal-Bhadra M.

ChemMedChem. 2010 Nov 8;5(11):1937-47. doi: 10.1002/cmdc.201000346.

PMID:
20836120
4.

Blockade of Rac1 activity induces G1 cell cycle arrest or apoptosis in breast cancer cells through downregulation of cyclin D1, survivin, and X-linked inhibitor of apoptosis protein.

Yoshida T, Zhang Y, Rivera Rosado LA, Chen J, Khan T, Moon SY, Zhang B.

Mol Cancer Ther. 2010 Jun;9(6):1657-68. doi: 10.1158/1535-7163.MCT-09-0906. Epub 2010 Jun 1.

5.

Anticancer and radio-sensitizing evaluation of some new thiazolopyrane and thiazolopyranopyrimidine derivatives bearing a sulfonamide moiety.

Ghorab MM, Ragab FA, Heiba HI, El-Hazek RM.

Eur J Med Chem. 2011 Oct;46(10):5120-6. doi: 10.1016/j.ejmech.2011.08.026. Epub 2011 Aug 27.

PMID:
21890248
6.

Synthesis and antitumor activity of pyrido [2,3-d]pyrimidine and pyrido[2,3-d] [1,2,4]triazolo[4,3-a]pyrimidine derivatives that induce apoptosis through G1 cell-cycle arrest.

Fares M, Abou-Seri SM, Abdel-Aziz HA, Abbas SE, Youssef MM, Eladwy RA.

Eur J Med Chem. 2014 Aug 18;83:155-66. doi: 10.1016/j.ejmech.2014.06.027. Epub 2014 Jun 13.

PMID:
24956552
7.

Design, synthesis and anticancer activity against the MCF-7 cell line of benzo-fused 1,4-dihetero seven- and six-membered tethered pyrimidines and purines.

Núñez MC, Díaz-Gavilán M, Conejo-García A, Cruz-López O, Gallo MA, Espinosa A, Campos JM.

Curr Med Chem. 2008;15(25):2614-31. Review.

PMID:
18855682
8.

A convenient synthesis and molecular modeling study of novel purine and pyrimidine derivatives as CDK2/cyclin A3 inhibitors.

Elgazwy AS, Ismail NS, Elzahabi HS.

Bioorg Med Chem. 2010 Nov 1;18(21):7639-50. doi: 10.1016/j.bmc.2010.08.033. Epub 2010 Aug 26.

PMID:
20851615
9.

Antitumor activity of CTFB, a novel anticancer agent, is associated with the down-regulation of nuclear factor-kappaB expression and proteasome activation in head and neck squamous carcinoma cell lines.

Skvortsov S, Skvortsova I, Stasyk T, Schiefermeier N, Neher A, Gunkel AR, Bonn GK, Huber LA, Lukas P, Pleiman CM, Zwierzina H.

Mol Cancer Ther. 2007 Jun;6(6):1898-908.

10.

[The effect of curcumin on bladder cancer cell line EJ in vitro].

Sun M, Yang Y, Li H, Su B, Lu Y, Wei Q, Fan T.

Zhong Yao Cai. 2004 Nov;27(11):848-50. Chinese.

PMID:
15810596
11.

Discovery of substituted 4-anilino-2-(2-pyridyl)pyrimidines as a new series of apoptosis inducers using a cell- and caspase-based high throughput screening assay. Part 1: structure-activity relationships of the 4-anilino group.

Sirisoma N, Kasibhatla S, Nguyen B, Pervin A, Wang Y, Claassen G, Tseng B, Drewe J, Cai SX.

Bioorg Med Chem. 2006 Dec 1;14(23):7761-73. Epub 2006 Aug 21.

PMID:
16919962
12.

New analogues of the anticancer E7070: synthesis and pharmacology.

Laconde G, Pommery N, Depreux P, Berthelot P, Hénichart JP.

J Enzyme Inhib Med Chem. 2003 Apr;18(2):89-94.

PMID:
12943191
13.

In vitro antitumor properties of a novel cyclin-dependent kinase inhibitor, P276-00.

Joshi KS, Rathos MJ, Joshi RD, Sivakumar M, Mascarenhas M, Kamble S, Lal B, Sharma S.

Mol Cancer Ther. 2007 Mar;6(3):918-25.

14.

In vitro and in vivo activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials.

DePinto W, Chu XJ, Yin X, Smith M, Packman K, Goelzer P, Lovey A, Chen Y, Qian H, Hamid R, Xiang Q, Tovar C, Blain R, Nevins T, Higgins B, Luistro L, Kolinsky K, Felix B, Hussain S, Heimbrook D.

Mol Cancer Ther. 2006 Nov;5(11):2644-58.

15.

Synthesis and biological evaluation of anilino substituted pyrimidine linked pyrrolobenzodiazepines as potential anticancer agents.

Kamal A, Reddy JS, Ramaiah MJ, Bharathi EV, Dastagiri D, Reddy MK, Pushpavalli SN, Pal-Bhadra M.

Bioorg Med Chem Lett. 2010 Sep 1;20(17):5232-6. doi: 10.1016/j.bmcl.2010.06.147. Epub 2010 Jul 29.

PMID:
20673627
16.

Induction of G(1)/S phase arrest and apoptosis by quercetin in human osteosarcoma cells.

Suh DK, Lee EJ, Kim HC, Kim JH.

Arch Pharm Res. 2010 May;33(5):781-5. doi: 10.1007/s12272-010-0519-4. Epub 2010 May 29. Erratum in: Arch Pharm Res. 2011 Jun;34(6):1035.

PMID:
20512478
17.

Synthesis and anticancer activity of chalcone-pyrrolobenzodiazepine conjugates linked via 1,2,3-triazole ring side-armed with alkane spacers.

Kamal A, Prabhakar S, Janaki Ramaiah M, Venkat Reddy P, Ratna Reddy Ch, Mallareddy A, Shankaraiah N, Lakshmi Narayan Reddy T, Pushpavalli SN, Pal-Bhadra M.

Eur J Med Chem. 2011 Sep;46(9):3820-31. doi: 10.1016/j.ejmech.2011.05.050. Epub 2011 May 30.

PMID:
21676506
18.

Myc down-regulation affects cyclin D1/cdk4 activity and induces apoptosis via Smac/Diablo pathway in an astrocytoma cell line.

Amendola D, De Salvo M, Marchese R, Verga Falzacappa C, Stigliano A, Carico E, Brunetti E, Moscarini M, Bucci B.

Cell Prolif. 2009 Feb;42(1):94-109. doi: 10.1111/j.1365-2184.2008.00576.x.

PMID:
19143767
19.

Curcumin downregulates the constitutive activity of NF-kappaB and induces apoptosis in novel mouse melanoma cells.

Marín YE, Wall BA, Wang S, Namkoong J, Martino JJ, Suh J, Lee HJ, Rabson AB, Yang CS, Chen S, Ryu JH.

Melanoma Res. 2007 Oct;17(5):274-83.

PMID:
17885582
20.

Biological profile of new apoptotic agents based on 2,4-pyrido[2,3-d]pyrimidine derivatives.

Cordeu L, Cubedo E, Bandrés E, Rebollo A, Sáenz X, Chozas H, Victoria Domínguez M, Echeverría M, Mendivil B, Sanmartin C, Palop JA, Font M, García-Foncillas J.

Bioorg Med Chem. 2007 Feb 15;15(4):1659-69. Epub 2006 Dec 12.

PMID:
17204425

Supplemental Content

Support Center